US OptionsDetailed Quotes
SAGE250117P27500
- 8.11
- 0.000.00%
15min DelayClose Jan 6 16:00 ET
0.00High0.00Low
8.11Open8.11Pre Close0 Volume0 Open Interest27.50Strike Price0.00Turnover480.02%IV-211.74%PremiumJan 17, 2025Expiry Date21.28Intrinsic Value100Multiplier11DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9194Delta0.0305Gamma0.29Leverage Ratio-0.0317Theta-0.0048Rho-0.27Eff Leverage0.0016Vega
Sage Therapeutics Stock Discussion
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
Sage Therapeutics has announced a strategic reorganization to support the launch of ZURZUVAE for postpartum depression and focus on pipeline development. The plan includes a workforce reduction of approximately 33%, affecting over 165 employees. This restructuring aims to extend the company's cash runway and position it for long-term ...
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
Sage Therapeutics (Nasdaq: SAGE) announced topline results from the Phase 2 LIGHTWAVE Study of dalzanemdor (SAGE-718) in treating mild cognitive impairment and mild dementia in Alzheimer's Disease. The study did not demonstrate a statistically significant difference from basel...
My research and analysis are not advice or recommendations. It's for information and knowledge purposes only. Any research , analysis, information, or other material received should not be construed as individualized investment advice. Investment decisions should be made as part of financial ...
oooooo
Gapping up
$Salesforce (CRM.US)$ jumped 6.2% following its earnings beat after the bell Wednesday. Adjusted earnings per share came in at $2.12 for the second quarter, versus the consensus estimate of $1.90, per Refinitiv. Revenue was $8.60 billion, topping the $8.53 expected. Goldman Sachs subsequently hiked its price target by $15 to $340 a share, suggestions 58% upside.
$UBS Group (UBS.US)$ popp...
No comment yet